The “bright and the dark side of the moon” in triplets. The top part of the figure shows the treatment schedule of the BZAG triplet combination and the rate of uMRD in peripheral blood, demonstrating the improved uMRD rate over time and the overlap of MRD rates between patients with TP53 aberrations and the entire population. The lower part of the figure shows the pros and cons of triplets in relapsed/refractory CLL. benda, bendamustine; del, deletion; FD, fixed duration; mut, mutation; pts, patients; ven, venetoclax.